GRI Bio, Inc.
GRIHealthcare|Biotechnology|US
$1.88
+0.33 (+21.29%)
DCF Value
$65.34
Tangible Book / Share
$5.70
Cash / Share
$6.06
Financials
Financial Snapshot
Market Cap
$4.1M
Enterprise Value
-$6.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$9.7M
Cash & Investments
$10.9M
Net Cash
$10.9M
Free Cash Flow (TTM)
-$10.4M
Operating CF (TTM)
-$10.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$10.9M
Quarterly Burn
$2.6M
Monthly Burn
$867.9K
Est. Runway
~4.2 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $612.7K | $3.8M | $109.0K | $90.0K | $9.0K | $1.8M | $5.0M | $8.2M | $10.9M | |
| Operating Cash Flow | -$2.4M | -$2.9M | -$3.7M | -$8.3M | -$1.1M | -$9.0M | -$8.6M | -$10.2M | -$10.4M | |
| Free Cash Flow | -$2.4M | -$2.9M | -$3.7M | -$8.3M | -$1.1M | -$9.0M | -$8.6M | -$10.2M | -$10.4M | |
| Capital Expenditure | -$2.2K | -$5.00 | -$2.0K | $0.00 | -$3.0K | -$8.0K | $0.00 | -$3.0K | -$3.0K | |
| Financing Cash Flow | $3.0M | $6.1M | -$4.0K | $15.7M | $1.0M | $10.8M | $11.8M | $13.4M | $16.2M |
R&D Spending
R&D (TTM)
$4.2M
R&D Intensity
—
R&D Growth vs Prior
-38.9%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $100.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $3.5M | $1.9M | $264.0K | $249.0K | $242.0K | $3.2M | $3.8M | $6.8M | $4.2M | |
| R&D % of Revenue | — | — | 264.0% | — | — | — | — | — | — | |
| SG&A | $800.1K | $1.3M | $1.2M | $813.0K | $2.0M | $8.2M | $4.5M | $5.2M | $5.5M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $100.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $612.00 | $735.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$612.00 | -$735.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $3.5M | $1.9M | $264.0K | $249.0K | $242.0K | $3.2M | $3.8M | $6.8M | $4.2M | |
| SG&A | $800.1K | $1.3M | $1.2M | $813.0K | $2.0M | $8.2M | $4.5M | $5.2M | $5.5M | |
| Operating Income | -$4.3M | -$3.2M | -$1.5M | -$1.1M | -$2.2M | -$11.4M | -$8.2M | -$12.0M | -$9.7M | |
| Interest Expense | $0.00 | $197.0K | $34.0K | $547.0K | $653.0K | $2.1M | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$4.3M | -$3.5M | -$2.5M | -$1.6M | -$3.2M | -$13.0M | -$8.2M | -$12.0M | -$9.7M | |
| Net Income | -$4.3M | -$3.5M | -$2.5M | -$1.6M | -$3.2M | -$13.0M | -$8.2M | -$12.0M | -$9.7M | |
| EPS (Diluted) | -822780.00 | -660968.00 | -4693.64 | -2827.16 | -47135.48 | -140450.24 | 0.33 | -121.80 | -43.70 | |
| EBITDA | -$4.3M | -$3.3M | -$1.4M | -$989.0K | -$2.6M | -$11.0M | -$8.2M | -$12.0M | -$9.7M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 4.92 | 0.10 | 1.80 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $612.7K | $3.8M | $109.0K | $90.0K | $9.0K | $1.8M | $5.0M | $8.2M | $10.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $637.6K | $3.9M | $674.0K | $96.0K | $312.0K | $2.9M | $5.6M | $8.6M | $11.3M | |
| Total Assets | $639.2K | $4.3M | $955.0K | $218.0K | $383.0K | $3.0M | $5.7M | $8.7M | $11.4M | |
| Total Current Liabilities | $486.3K | $807.5K | $2.2M | $4.9M | $2.0M | $2.7M | $1.6M | $2.6M | $1.1M | |
| Long-Term Debt | $0.00 | $0.00 | $14.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $486.3K | $1.1M | $2.4M | $4.9M | $2.0M | $2.7M | $1.7M | $2.7M | $1.1M | |
| Stockholders' Equity | $152.9K | $3.2M | -$1.5M | -$4.7M | -$1.6M | $259.0K | $4.0M | $6.0M | $10.3M | |
| Retained Earnings | -$4.3M | -$7.8M | -$12.6M | -$15.3M | -$18.5M | -$31.5M | -$39.7M | -$51.7M | -$55.3M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.4M | -$2.9M | -$3.7M | -$8.3M | -$1.1M | -$9.0M | -$8.6M | -$10.2M | -$10.4M | |
| Capital Expenditure | -$2.2K | -$5.00 | -$2.0K | $0.00 | -$3.0K | -$8.0K | $0.00 | -$3.0K | -$3.0K | |
| Free Cash Flow | -$2.4M | -$2.9M | -$3.7M | -$8.3M | -$1.1M | -$9.0M | -$8.6M | -$10.2M | -$10.4M | |
| Investing Cash Flow | -$2.2K | $0.00 | -$2.0K | -$3.8M | -$3.0K | -$8.0K | $0.00 | -$3.0K | -$3.0K | |
| Financing Cash Flow | $3.0M | $6.1M | -$4.0K | $15.7M | $1.0M | $10.8M | $11.8M | $13.4M | $16.2M | |
| Issuance of Stock | $3.0M | $5.0M | $0.00 | $15.5M | $0.00 | $12.3M | $13.1M | $15.6M | $17.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$124.0K | $0.00 | -$1.0K | -$1.0K | $0.00 | |
| Net Debt Issuance | $0.00 | $1.1M | -$4.0K | $244.0K | $1.3M | $1.3M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $25.0K | $388.0K | $148.0K | $793.0K | $596.0K | |
| Net Change in Cash | $612.7K | $3.2M | -$3.7M | $3.6M | -$81.0K | $1.8M | $3.2M | $3.2M | $5.8M |
Dilution Tracker
Shares outstanding grew 10917.1% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+10917.1%
Stock Issuance (TTM)
$17.5M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 4.92 | 0.10 | 1.80 | |
| Change vs Prior % | — | 0.0% | 0.0% | 1202.1% | -90.0% | 36.0% | 311426.1% | -98.0% | 1738.7% | |
| Stock Issuance | $3.0M | $5.0M | $0.00 | $15.5M | $0.00 | $12.3M | $13.1M | $15.6M | $17.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$124.0K | $0.00 | -$1.0K | -$1.0K | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $25.0K | $388.0K | $148.0K | $793.0K | $596.0K |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 0.0% | — | — | — | — | — | — | |
| Operating Margin % | — | — | -1459.0% | — | — | — | — | — | — | |
| Net Margin % | — | — | -2531.0% | — | — | — | — | — | — | |
| EBITDA Margin % | — | — | -1384.0% | — | — | — | — | — | — | |
| FCF Margin % | — | — | -3708.0% | — | — | — | — | — | — | |
| ROE % | -2819.8% | -107.8% | 174.1% | 33.0% | 198.0% | -5033.6% | -203.5% | -199.0% | -134.0% | |
| ROA % | -674.7% | -81.0% | -265.0% | -715.1% | -839.9% | -441.0% | -143.0% | -138.0% | -84.9% | |
| ROIC % | -2820.5% | -88.8% | 130.5% | 95.7% | 235.2% | -4171.1% | -198.4% | -197.0% | -93.8% | |
| R&D / Revenue % | — | — | 264.0% | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -20.1% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 26.9% | 53.7% | 27.2% | -110.8% | -408.6% | 27.7% | -45.4% | |
| Net Income | 0.0% | 19.7% | 26.9% | 38.4% | -106.4% | -305.3% | 37.0% | -45.7% | |
| EPS (Diluted) | 0.0% | 19.7% | 99.3% | 39.8% | -1567.2% | -198.0% | 100.0% | -37009.1% | |
| Operating Cash Flow | 0.0% | -21.6% | -28.5% | -124.3% | 86.9% | -728.6% | 4.2% | -18.3% | |
| Free Cash Flow | 0.0% | -21.5% | -28.6% | -124.2% | 86.9% | -727.0% | 4.3% | -18.3% | |
| R&D Expense | 0.0% | -46.4% | -86.0% | -5.7% | -2.8% | 1235.5% | 16.6% | 81.0% | |
| SG&A Expense | 0.0% | 58.9% | -6.0% | -32.0% | 145.6% | 308.4% | -45.2% | 15.5% | |
| Total Assets | 0.0% | 568.9% | -77.7% | -77.2% | 75.7% | 671.8% | 94.1% | 51.0% | |
| Book Value / Share | 0.0% | 2001.4% | -145.2% | 75.0% | -244.0% | 111.7% | -99.5% | 7331.1% | |
| Debt | 0.0% | 0.0% | -1.2% | 975.6% | -81.4% | -97.9% | 750.0% | -40.3% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 1202.1% | -90.0% | 36.0% | 311426.1% | -98.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.33
10Y Low / Med / High0.11 / 478.66 / 57536.40
EV/EBITDA0.70
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$65.34
Tangible Book / Share
$5.70
Net Current Assets / Share
$4.68
Graham Net-Net
$5.46
Cash / Share
$6.06
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -12.00 | -14.94 | -2104.13 | -2748.66 | -8.00 | -0.12 | 1194.67 | -0.06 | -0.04 | |
| P/S Ratio | 0.00 | 0.00 | 87995.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 57536.40 | 2738.05 | -6051.97 | -19085.07 | -269.01 | 101.59 | 478.66 | 0.11 | 0.33 | |
| EV/EBITDA | -2040.56 | -2692.62 | -6358.23 | -91164.20 | -170.95 | -2.24 | -233.88 | 0.62 | 0.70 | |
| EV/Revenue | 0.00 | 0.00 | 87997.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-6.29
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$367.1K | -$196.3K | -$16.7K |
| EPS | $-3.75 | $-2.00 | $-0.17 |
| # Analysts (EPS) | 2 | 2 | 1 |
Dividends
Frequency
Irregular
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Dec 29, 2008 | $0.00 | Irregular |